Driven by the value economy, consumers are very enthusiastic about all kinds of cosmetics, whether it is beauty cosmetics or care products. Years of development have also enabled the cosmetics industry to successfully have a large number of fans. According to the data of relevant institutions, in 2020, the cosmetics market in China has reached 756,543.8 billion US dollars, and it is estimated that this figure will climb to 654.38+0.478 billion US dollars and 543.8+0 in 2026.
Medical beauty industry brings Yan value economy 4.0
At present, the cosmetic industry is still booming, but with the maturity of cosmetic technology in the world, the medical beauty industry in China has gradually developed. The medical beauty industry with facial adjustment and micro-plastic surgery as its main selling points has successfully brought the Yan value economy into the 4.0 era. Although it is a medical act, there is no doubt that there are certain risks in the medical beauty industry. Some illegal and illegal materials used by informal medical beauty institutions can easily damage the rights and interests of consumers, but the pursuit of beauty still makes many women choose to try.
According to the data of relevant institutions, around 20 16 years ago, the market size of China's medical and beauty industry was only 77.6 billion yuan, but by 20176.9 billion yuan, the annual growth rate was higher than the global level. In 2020, the industry will be affected by special health events, but with the gradual control of special health events in China,
According to the data, it is estimated that in 20021year, the market size of medical and beauty industry in China will reach 227.4 billion yuan. In addition to the increase in market size, the number of medical beauty users is also increasing. By April of 20021year, the number of medical and beauty users in China has reached180.73 million, and it is expected to be 1520 in 2020.
Yan value business of "profiteering"
Perhaps the most representative enterprise is Aimeike, which was established in 2004. As a leading enterprise in the medical beauty industry, Aimeike, which produces hyaluronic acid, is also known as the "Big Three of Medical Beauty" together with Haohaishengke and Huaxi Bio. According to the data of relevant institutions, the market share of Aimeike hyaluronic acid will reach 27.2% in 2020, and it has successfully become the largest supplier of hyaluronic acid-based skin fillers in China.
This achievement is inseparable from the listing of Aimeike. In September 2020, Aimeike was successfully listed on Shenzhen Stock Exchange. In less than five months, its share price once climbed to 133 1.02 yuan per share, which was called "Medical Beauty Maotai" by many people. At the same time, Aimeike also submitted an IPO application recently, preparing to seize the main board of the Hong Kong Stock Exchange. if
Why can beauty lovers who are engaged in the medical beauty industry get the "love" of the capital market? In fact, this can be seen from Amy's financial report. According to Aimeike's financial report, in 2020, Aimeike's revenue reached 709 million yuan, gross profit reached 549 million yuan, and gross profit margin was 9 1.4%, which was very exaggerated.
In the first quarter of 20021,Aimeike achieved revenue of 259 million yuan, up 227.52% year-on-year, gross profit rate of 92.5% and net profit of 1.7 1 billion yuan, up 296.5% year-on-year. It can be said that more than 90% gross profit margin has brought a very strong profitability to Aimeike.
Amy's "dilemma"
It is worth mentioning that Aimeike's very high gross profit margin is closely related to the decline in the price of hyaluronic acid raw materials in recent years. According to the data, during the period from 20 17 to 2020, the price of hyaluronic acid fell from 2 10 yuan to 160 yuan, and the gross profit margin of Aimeike also increased from 87.2% to 92%.
Compared with Huaxi Bio's three product lines of hyaluronic acid products, cosmetics and food, Aimeike's single product makes the company lack the ability to resist risks. In order to solve this problem, Aimeike has increased its investment in three product lines: medical devices, chemicals and biological drugs.
Moreover, in the application for listing on the main board submitted by Aimeike to the Hong Kong Stock Exchange, it is also indicated that all the raised funds will be used for the company's business development, such as improving research and development capabilities and conducting business cooperation with domestic and foreign countries. At the same time, in June of 20021,Aimeike said that it was prepared to invest about 886 million yuan in a company whose main business is the production of botulinum toxin A and acquire its 25.4% equity.
Although a month later, Aimeike said that it would cancel the acquisition proposal after careful study, it also showed Aimeike's ambition to expand its business. After all, in addition to the advantages of high profit and high growth, the medical beauty industry also has the characteristics of just need, easy consumption and threshold. It can be said that any enterprise with a single product type will not go far. However, the current market value is 654.38 billion yuan. Can Aimeike, who chooses to go public for the second time, use more funds to support it?